louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02869230: ROLL vs WGLL for Non-palpable Breast Lesions
Official title: Radioguided Occult Lesion Localization (ROLL) is Superior a to the Wire-Guided Lesion Localization (WGLL)? Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: Breast cancer
Non palpable breast lesions
radioguided occult lesion localization
Lead sponsor: Instituto Nacional de Cancerologia, Columbia
Sponsor class: OTHER_GOV
First posted: 2016-08-16
Enrollment: 129
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Here were present a controlled clinical trial comparing wire-guided lesion localization (WGLL)and radioguided occult lesion localization (ROLL) in patients treated for nonpalpable breast lesions at the Instituto Nacional de Cancerología (National Cancer Institute)in Bogotá,Colombia.

Detailed description: The aim of this study was to compare the radioguided occult lesion localization (ROLL) technique with the wire-guided lesion localization (WGLL) technique to assess the optimal localization and excision of nonpalpable breast lesions in patients at a unique reference medical center.

A controlled clinical trial was designed to compare the WGLL and ROLL techniques in women presenting with breast lesions diagnosed by mammography or ultrasound at the Instituto Nacional de Cancerología in Bogotá, Colombia from March 2006 to June 2011.

This study evaluate 129 patients; 64 (49.6%) patients were treated using ROLL and 65 (51.4%) using WGLL.

Eligibility criteria: Inclusion Criteria:

* Female patients older than 18 years
* Lesions suggesting malignancy (BIRADS 4 and 5)
* Solid nodules in postmenopausal women (BIRADS 3 mammograms).

Exclusion Criteria:

* Pregnant or nursing
* Patients with suspected multifocal or multicentric disease (suspicious microcalcifications scattered over a wide area on mammography)
* Patients with retro-areola lesions (less than 2 cm away from the nipple)
* Lesions that had previously undergone surgery or excisional biopsies in the compromised breast

Primary outcomes:
measure: Localization of nonpalpable breast lesion (percentage)
timeFrame: 30 days
Secondary outcomes:
measure: presence of malignancy
timeFrame: 30 days
Other outcomes:
Locations:
Study officials:
affiliation: Instituto Nacional de Cancerologia de Mexico
name: faustino bastidas, md
role: STUDY_CHAIR
References:
Clinical trial NCT06723730: ADDITIONAL EFFECTS OF MOBILIZATION WITH MOVEMENT WITH UPPER QUADRANT CORE STRENGTHENING IN ROTATOR CUFF RELATED PAIN:A RANDOMIZED CONTROLLED TRAIL
Official title: ADDITIONAL EFFECTS OF MOBILIZATION WITH MOVEMENT WITH UPPER QUADRANT CORE STRENGTHENING IN ROTATOR CUFF RELATED PAIN:A RANDOMIZED CONTROLLED TRAIL
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Rotator Cuff Syndrome
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-12-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized Control Trial
Primary purpose: TREATMENT

Brief summary: This study is a randomised control trial and the purpose of this study is to determine the additional effects of mobilization with movement with upper quadrant core strengthening in rotator cuff related pain

.

Detailed description: The purpose of this study is to determine the effects of mobilization with movement with upper quadrant core strengthening in rotator cuff related shoulder pain on A. Pain B. Range of motion C. Propioception D. Kinesiophobia

Data collection procedure: Participants of interest would be approached and explained about the research. Informed written consent will be taken. Recruited participants will be allocated to either of the groups through a sealed opaque envelope method.

Eligibility criteria: Inclusion Criteria:

* Age 18-65 years
* Both genders
* Unilateral shoulder pain of traumatic origin
* Scoring should be less than 8 on numeric pain rating scale
* Symptoms lasting more than 6 weeks
* Pain on active shoulder movement
* Pain provoked by atleast three of the following tests. A. Neer test B. Hawkins-Kennedy test C. Empty Can test D. Full Can test E. Painfull Arc test F. Resisted external rotation test
* Patients reffered by a rehabilitation and orthopedic specialistwith diagnosis of rotator cuff injury, subacromial impingement syndrome, subacromial pain

Exclusion Criteria:

* History and Clinical presentation compatible with complete rotator cuff or bicep brachia rupture
* Adhesive capsulitis
* History of dislocation
* Glenohumeral osteoarthritis
* Cancer
* Auto-immune inflammatory conditions and infection
* Positive joint integrity tests ( Ant. and Post. Drawer tests)
* Hill sachs lesions
* Bankarts lesions
* Cervical rib
* Previous shoulder or neck surgery or fracture
* Familiar pain provoked by neck movements
* Presence of radicular sign
* Diagnosis of fibromyalgia
* Clinical depression
* Rheumatoid arthritis
* Poor bone quality ( osteoporosis)
* Vertobrobasilar insufficiency test

Primary outcomes:
measure: Pain intensity
timeFrame: 4 weeks
measure: Range of motion
timeFrame: 4 weeks
measure: Proprioception
timeFrame: 4 weeks
measure: Kinesiophobia
timeFrame: 4 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT03794830: The Influence of the Manipulation of the Sacroiliac Joint on Low Back Pain
Official title: The Influence of the Manipulation of the Sacroiliac Joint on Low Back Pain With or Without Radiation to Lower Limbs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Sacroiliac Disorder
Keywords: sacroiliac joint
low back pain
Osteopathic manipulation
Lead sponsor: University of Extremadura
Sponsor class: OTHER
First posted: 2019-01-07
Enrollment: 151
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary focus of this study is to know the influence of sacroiliac joint manipulation on low back pain with or without radiation to lower limbs, in the lumbopelvic-hip joint

Detailed description: One of the main problems faced by physiotherapists in primary care is low back pain with or without radiation to lower limbs. Nowadays, there are a lot of types of low back pain interventions, yet despite the vast amount of research findings, the evidence remains contradictory and inconclusive: Pharmacological treatments like NSAIDs have shown result in acute low back pain but not in chronic pain; conservative interventions (ultrasound, interferential currents, mechanical traction and massage) have been studied and found ineffective.

A total of 151 low back pain patients with or without radiation to lower limbs between 18-70 years old derived from the Physiotherapy Unit of Gévora Health Center (Badajoz, Spain) voluntarily entered the study

Eligibility criteria: Inclusion Criteria:

* dysfunction or sacroiliac joint hypomobility (SI)
* having stopped taking anti-inflammatory medicines or analgesics three days before the study began

Exclusion Criteria:

* destructive injuries of the spine and pelvis
* fractures
* lumbar surgery
* sacroiliac instability
* spondylolisthesis
* pregnancy in progress
* cauda equina syndrome
* abdominal aneurysm
* infection
* inflammatory arthritis
* tumors
* osteoporosis

Primary outcomes:
measure: visual analogue scale (VAS)
timeFrame: 1 week
measure: Oswestry disability index (ODI)
timeFrame: 1 week
measure: Roland Morris questionnaire
timeFrame: 1 week
measure: digital algometer (Wagner, FPIX model)
timeFrame: 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: Badajoz
country: Spain
facility: Universidad de Extremadura
Study officials:
affiliation: Universidad de Extremadura. Facultad de Medicina (Badajoz). Spain
name: Jose Antonio JA Rodriguez-Pastor, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Universidad de Extremadura. Facultad de Medicina (Badajoz). Spain
name: Mª Dolores MD Apolo-Arenas, PhD
role: STUDY_DIRECTOR
affiliation: Universidad de Extremadura. Facultad de Medicina (Badajoz). Spain
name: Berta BC Caro-Puértolas, PhD
role: STUDY_DIRECTOR
affiliation: Universidad de Extremadura. Facultad de Medicina (Badajoz). Spain
name: Alejandro AC Caña-Pino, PT,MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06592430: The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns
Official title: The Impact of Communication With Healthcare Providers Via WeChat on Survival Outcomes for Lung Cancer Patietns
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Lung Cancer
Lead sponsor: Shanghai Pulmonary Hospital, Shanghai, China
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagonosed with lung cacner

Brief summary: The use of smartphone-based WeChat applications offers significant advantages in cancer patient education, rehabilitation monitoring, and postoperative symptom management. Through the WeChat platform, patients can access health education materials, engage in online consultations, and interact with doctors and other patients at any time. This ongoing education and psychological support help alleviate patient anxiety and improve their quality of life. This study aims to conduct a prospective observational study in our hospital to explore the impact of WeChat communication on the prognosis of patients with different histological types and stages of lung cancer.


Eligibility criteria: Inclusion Criteria:

* (1) Lung cancer patients receiving treatment at Shanghai Pulmonary Hospital (2) ECOG performance status of 0-2 (3) No other serious internal medical conditions (such as severe heart failure, hypertensive crisis, diabetic ketoacidosis, severe liver or kidney impairment, etc.) (4) No history of other malignant tumors in the past 5 years, and no detection of other tumor history during follow-up after lung cancer diagnosis (5) Relevant pathological results

Exclusion Criteria:

* (1) Patients refused enrollment in this study; （2）Patients refused follow-up.

Primary outcomes:
measure: Overall survival (OS)
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07022730: Prophylactic Noradrenaline Infusion and Its Impact on Post-induction Hypotension
Official title: The Novel Use of Prophylactic Noradrenaline Infusion and Its Impact on Post-induction Hypotension in Patients With Surgical Sepsis, a Double Blind Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Post Induction Hypotension
Sepsis
Keywords: Hypotension
noradrenaline
sepsis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-06-15
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: researchers aim to evaluate the influence of prophylactic noradrenaline infusion on post-induction hypotension

Detailed description: If post-induction hypotension is not addressed promptly, it can lead to severe complications such as reduced blood flow, acute kidney damage, and myocardial ischemia. As a result, early detection and proactive intervention are crucial. Researchers of the current study decided to investigate impact of noradrenaline administered as a prophylaxis on post induction hypotension

Eligibility criteria: Inclusion Criteria:

* Adult patients with sepsis undergoing source control surgery.

Exclusion Criteria:

* Patient refusal
* Patient with cardiac pathology ( ischemic heart disease or heart failure)
* Preoperative hemodynamic instability (defined as MAP \< 65 mmHg)
* Rapid sequence induction

Primary outcomes:
measure: Incidence of post induction hypotension in both groups
timeFrame: Within the first 20 minutes of induction.
Secondary outcomes:
measure: Incidence of acute kidney injury
timeFrame: 7 days post operative
measure: Incidence of myocardial infarction
timeFrame: 7 days postoperative
measure: Incidence of stroke
timeFrame: 7 days postoperative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
state: Cairo Governorate
Study officials:
References:
citation: Goertz AW, Lindner KH, Seefelder C, Schirmer U, Beyer M, Georgieff M. Effect of phenylephrine bolus administration on global left ventricular function in patients with coronary artery disease and patients with valvular aortic stenosis. Anesthesiology. 1993 May;78(5):834-41. doi: 10.1097/00000542-199305000-00005.
citation: Czajka S, Putowski Z, Krzych LJ. Post-induction hypotension and intraoperative hypotension as potential separate risk factors for the adverse outcome: a cohort study. J Anesth. 2023 Jun;37(3):442-450. doi: 10.1007/s00540-023-03191-7. Epub 2023 Apr 21.
citation: Tangkulpanich P, Angkoontassaneeyarat C, Trainarongsakul T, Jenpanitpong C. Factors Associated with Postintubation Hypotension Among Patients with Suspected Sepsis in Emergency Department. Open Access Emerg Med. 2023 Nov 14;15:427-436. doi: 10.2147/OAEM.S426822. eCollection 2023.
Clinical trial NCT00511030: Assessment of Stability of Mail-in Capillary Hemoglobin A1c Test Kit
Official title: Assessment of Stability and Ease of Use of a Mail-in Capillary Blood Hemoglobin A!c Sample Kit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Keywords: Diabetes
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
First posted: 2007-08-03
Enrollment: 23
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male and females, age 1-17, receiving care in the Endocrine clinic at Children's Mercy Hospital who require HbA1c for standard of care.

Brief summary: The purpose of this study is to determine the stability of capillary HBA1c blood samples collected by the participant with this kit and mailed to the laboratory at Children's Mercy Hospital.

Detailed description: Participants are given home lab kit for obtaining HbA1c by capillary blood and shipping it to Children's Mercy Hospital and Clinics. They will mail in sample before their next visit and this result will be compared to the HbA1c performed during this visit.

Eligibility criteria: Inclusion Criteria:

* Male or female diabetic patients ages 1-17 years who have an A1c test drawn within 24 hours
* Participants receiving medical care in the Endocrine Clinic at Children's Mercy Hospital

Exclusion Criteria:

* Not meeting above inclusion criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: Children's Mercy Hospital
state: Missouri
Study officials:
affiliation: Children's Mercy Hospital Kansas City
name: Uttam Garg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00925730: Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
Official title: Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atopic Dermatitis
Keywords: Atopic dermatitis
AD
pimecrolimus
blood
absorption
systemic
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2009-06-22
Enrollment: 20
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e. areas treated wrapped in a plastic film) over 8 days in patients with moderate to severe atopic eczema.


Eligibility criteria: Inclusion Criteria:

* Patients 2 - 18 years of age
* Patients with a diagnosis of moderate to severe atopic dermatitis, assessed by a score ≥ 3 at the Investigator's Global Assessment. AD to involve at least 30% of their body surface area as determined by the rule of nine or the Lund and Browder chart.

Exclusion Criteria:

* Erythrodermic patients with Netherton's syndrome
* Patients with known serious adverse reactions or hypersensitivity to any of the excipients of the study medication
* Patients with a history of cancer, skin malignancy or lymphoproliferative disorders or of immunocompromise, including a positive HIV (ELISA and Western blot), Hepatitis B surface antigen (HBsAg) or Hepatitis C test result

Other protocol-defined inclusion/exclusion criteria may apply

Primary outcomes:
measure: Pimecrolimus blood concentration
timeFrame: Days 1, 9, 16
Secondary outcomes:
measure: Efficacy as assessed by the Eczema Area and Severity Index and the Investigators Global Assessment of disease severity. Efficacy outcomes were of an exploratory nature in this study.
timeFrame: Days 1, 9, 16
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: Novartis Investigative Site
city: Frankfurt am Main
country: Germany
facility: Novartis Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Thaci D, Kaufmann R, Bieber T, Hanfland J, Hauffe S, Koehne-Voss S, Waldmeier F. Percutaneous absorption of pimecrolimus is not increased in patients with moderate to severe atopic dermatitis when pimecrolimus cream 1% is applied under occlusion. Dermatology. 2010;221(4):342-51. doi: 10.1159/000320125. Epub 2010 Nov 22.
Clinical trial NCT01652430: Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder
Official title: Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: PTSD
Suicidal Ideation
Keywords: PTSD
Suicidal ideation
Cognitive processes
Lead sponsor: VA Eastern Colorado Health Care System
Sponsor class: FED
First posted: 2012-07-30
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The sample for the current project will be recruited from the group of veterans receiving or eligible to receive outpatient mental health services at the Denver VA Medical Center who have served in combat who may or may not have a diagnosis of PTSD.

Brief summary: This study plans to examine if symptoms of PTSD affect how Veterans who have served in combat think and react to certain information, and whether or not this has an influence on suicidal thoughts.


Eligibility criteria: Inclusion Criteria:

1. History of combat service
2. Diagnosis of PTSD confirmed by the CAPS or
3. No current diagnosis of PTSD
4. Age 18-65

Exclusion Criteria:

1. Inability to adequately respond to questions regarding the informed consent procedure.
2. History of significant neurological disease
3. Diagnosis of Schizophrenia or other Psychosis
4. Alcohol abuse/dependence or illicit drug use in the two weeks prior to testing
5. No history of combat service

Primary outcomes:
measure: Beck Scale for Suicidal ideation
timeFrame: One time
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Denver VA Medical Center
state: Colorado
Study officials:
affiliation: VA Eastern Colorado Healthcare System/MIRECC
name: Nazanin Bahraini, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03027830: iFR Pressure Wires in Assessment of the Provisional Side-branch Intervention Strategy for Bifurcation Lesions
Official title: Physiological and Clinical Assessment of the Provisional Side-branch Intervention Strategy for Coronary Bifurcation Lesions Using iFR Pressure Wires
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Bifurcation Lesions
Keywords: Provisional side-branch intervention strategy
iFR
Pilot study
Lead sponsor: Nova-Med Medical Research Association
Sponsor class: OTHER
First posted: 2017-01-23
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DEVICE_FEASIBILITY

Brief summary: Even in the era of drug-eluting stents, bifurcation lesions remain one of the most challenging lesion subsets in coronary intervention practice. This study was performed to evaluate the functional outcomes of pressure wires (IFR)-guided jailed side-branch intervention strategy.

Detailed description: Fractional flow reserve (FFR) measurements require minimal and constant microvascular resistance which is routinely achieved by intravenous adenosine infusion. Adenosine-induced hyperemia establishes an optimal vascular environment for FFR measurement. However, breathlessness and chest tightness are common adverse events during adenosine infusion and severe asthma occurs occasionally. The Introduction of an adenosine-independent index (instantaneous wave-free ratio \[iFR\]) into clinical practice offered easier and hyperemia-free method for lesion assessment.

Physiological changes and clinical evaluation of iFR warrants further research. Therefore, the investigators conducted this study to evaluate the functional aspects of iFR-guided provisional jailed side-branch intervention strategy and compare clinical endpoints to conventional non-iFR-guided operations.

Eligibility criteria: Inclusion Criteria:

* Patients with acute coronary syndrome
* Jailed side-branch of a vessel size \> 2 mm
* Vessel length \> 40 mm
* Lesion length \< 10 mm by visual estimation

Exclusion Criteria:

* Significant stenosis in the left main coronary artery or the main branch proximal to the stented segment
* Totally occluded bifurcation lesions
* Primary myocardial disease
* Serum creatinine level of ≥ 2.

Primary outcomes:
measure: Physiological evaluation of iFR-guided intervention
timeFrame: 6-month
Secondary outcomes:
measure: length of hospital stay
timeFrame: 6-month
measure: Procedure time
timeFrame: 30-day
measure: Fluoroscopy time
timeFrame: 30-day
measure: In-hospital heart failure class
timeFrame: 30-day
measure: 6-month heart failure class
timeFrame: 6-month
measure: Post-PCI angina
timeFrame: 6-month
measure: Ejection fraction at 6 months' post operation
timeFrame: 6-month
measure: The amount of dye injection for angiography
timeFrame: 30-day
Other outcomes:
Locations:
Study officials:
References: